<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> globally </plain></SENT>
<SENT sid="1" pm="."><plain>At diagnosis, more than 70% of patients have nonmetastatic disease </plain></SENT>
<SENT sid="2" pm="."><plain>Cure rates for early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> have improved with primary screening, improvements in surgical techniques and advances in adjuvant chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Despite optimal primary treatment, 30-50% of these patients will still relapse </plain></SENT>
<SENT sid="4" pm="."><plain>While <z:hpo ids='HP_0011420'>death</z:hpo> will result from widespread <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e>, patients with small volume oligometastatic disease are still considered curable with aggressive multimodality therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Hence, early detection of <z:e sem="disease" ids="C0549379" disease_type="Neoplastic Process" abbrv="">relapsed cancer</z:e> when it is still amenable to resection expands the window of opportunity for cure </plain></SENT>
<SENT sid="6" pm="."><plain>Here, the authors review the modalities currently employed in clinical practice and the evidence supporting intensive surveillance strategies </plain></SENT>
<SENT sid="7" pm="."><plain>The authors also discuss ongoing clinical trials examining specific surveillance programs and emerging modalities that may be deployed in the future for early detection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
</text></document>